More than half of commercially insured patients who initiated HIV pre-exposure prophylaxis (PrEP) persisted on therapy for 12 months, compared with one-third of Medicaid patients, according to a new study.
Lower PrEP persistence was related to being female, younger, black, living in a rural area, and/or having Medicaid insurance coverage.